| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497711 | BIOXCEL | NA |
Jun, 2039
(15 years from now) | |
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11517524 | BIOXCEL | NA |
Jun, 2039
(15 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
Igalmi is owned by Bioxcel.
Igalmi contains Dexmedetomidine Hydrochloride.
Igalmi has a total of 4 drug patents out of which 0 drug patents have expired.
Igalmi was authorised for market use on 05 April, 2022.
Igalmi is available in film;buccal, sublingual dosage forms.
Igalmi can be used as acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration.
The generics of Igalmi are possible to be released after 26 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic